Recently, it was observed that pediatric tumors (soft tissue sarcomas or medullary thyroid cancer) harboring either an RET-fused or RET-mutated pathogenic somatic alteration show clinical response to the RET inhibitor Selpercatinib [134]. Here, RET is linked to soft tissue sarcoma.